



US 20100173296A1

(19) **United States**

(12) **Patent Application Publication**
Moreau

(10) **Pub. No.: US 2010/0173296 A1**
(43) **Pub. Date: Jul. 8, 2010**

(54) **METHODS OF STRATIFYING ADOLESCENT
IDIOPATHIC SCOLIOSIS, ISOLATED
NUCLEIC ACID MOLECULES FOR USE IN
SAME AND KITS USING SAME**

Related U.S. Application Data

(60) Provisional application No. 60/895,490, filed on Mar. 19, 2007, provisional application No. 60/908,417, filed on Mar. 28, 2007.

(75) Inventor: **Alain Moreau, Montreal (CA)**

Publication Classification

Correspondence Address:
**GOUDREAU GAGE DUBUC
2000 MCGILL COLLEGE, SUITE 2200
MONTREAL, QC H3A 3H3 (CA)**

(51) **Int. Cl.**
C12Q 1/68 (2006.01)
C12Q 1/02 (2006.01)
G01N 33/53 (2006.01)
(52) **U.S. Cl.** **435/6; 435/29; 435/7.2**

(73) Assignee: **CHU Sainte-Justine**

(57) **ABSTRACT**


(21) Appl. No.: **12/531,740**

(22) PCT Filed: **Mar. 19, 2008**

(86) PCT No.: **PCT/CA08/00524**

§ 371 (c)(1),
(2), (4) Date: **Sep. 17, 2009**

A method of stratifying a subject having adolescent idiopathic scoliosis (AIS) comprising: providing a cell sample isolated from the subject; detecting Paired-like homeodomain transcription factor 1 (Pitxi) expression in the cell sample; whereby the results of the detecting step enables the stratification of the subject having AIS as belonging to an AIS subclass.



AIS	Controls
N= 46	N= 29

Figure 1

_____CCCAAATTGTCTATCTGTGATAGTGGCTGTGCCCTTCGGGCCCTGAGCACCTGTGTCTGTG
CA
-10006
GCAGTCAGATATCTGGAGGGAGACTGAGGCACTGGCTGCAGAGCTTGTGATCATGAGAGAGACTCACTA
GG
-9940
ACTACAGATGGGTAAACTGAGGCCTTCGAGGGGGCAGCTCCAGAAAAGGCAGGGGCCATAATGTCTCACC
TT
-9869
CATATTTCCCGTGCCAAGCTGTGGCCTTCTGCATTCATGGCAGATGAGTGGACAAAGGCTGATGGACTG
AT
-9798
GGAGAAACAAAGGGATAGATGGAGCAGCTGGGCAGCTCAGCAAATGATGCTGCAATGATCTGCTTCCAA
CT
-9727
CACCTCAAATCCATCCTTCTCTCCAGGCAGAGTGGGCTTTTAAGATACACATCTGGCCAGGTCTCTC
AC
-9656
TGTTCAAACCCCTTCATCTGCTCCTTTTGCCTTCAGGATAACATCCCACCCTCCTATCAAGGACTATGG
AG
-9585 **(-9543)G RS4976262**
CCCTGTGGGATCTGGTCCCCTTGCATTCCTTCCCACTTCCCTTCCCTATGCCCTGCCTTCTCATCTGT
TC
-9514
CAGTGTCTATTATGAAGCCACACGTTCTTCCCTTTATTATCAAGCATACCACAGTTTATCTCACCTCAGAG
GC
-9443
TTTGACAGTATATTTTCCCTAGGGAGGGTCCCCAGGTGGTAGAAAAACGGTTACAGCCAACTCCTCCA
TG
-9372 **(-9323)T RS39881**
TGTCACCTCAAGACCCCTTCAACAGCAGGCTGCAGATTTCTTCCAGCACTGTGCTCCAACIGTGAATG
GA
-9301
TTTCTGTGTCTGCCTCCTTGACTCAACCCAAATGAACAAGAGCCATCTATCTCTGTATCTCTGCAATCA
CA
-9230
GGCACAAAATAGGTGCTCTCTACATTTTTTCCAACCTGAGAGGCCATTCTAGAAGGGTCTCAGGCCAG
GT
-9159
TCTGTCCAGTATTCATGCAGATGCTGACAGGACTGCAATTAATAAATACTTGAGATGCCCAAATGCC
CA
-9088
AATAGCTTCTCATTTTGTCTTACTACCAATAATTGCACAGTGCAATAGAATAATGCTCAAATACATTA
AC
-9017 **(-8969)C RS254550**
ATCTTACTTGATCCTAGGGGGTCTCTCTACTTTTAAAGCCTCAAACCTCCTCCCTCCTCACAGGTGAAA
AG
-8946
GGGAGTACAAATACATTCCCTCCCTTGCTCTGCGGATCCATTCCTACAGGTAGTCAAGACTCTGAGCTT
CC
-8875
CCTCTGACTTTCTGGCAGTGTCTCACCTCTCCCCACAGATGAGTGCAGGAACAATTCTAACAGACTTCA
GA
-8804
CTCTTCCAACAGAGCCAAATCCCTCCCATCACGTTGGAGTGGACTTGCTACCCACACCATCAACAGGCC
CC
-8733
TGAGAACTTACAGGGCAGGGGCTTCTTTGGTAAAACCAACCCTTCTCTCCACCAGCTCAGAGAAGT
TG
-8662



TTCCAGATAGATGCCAGGATTCTTGGAGGAGCATGGTATTCTGGGGTGGAGCCTCTGACCCTGGCCAA
 CC
 -8591
 AAAGGCTGAGCCACTCTTCCCCACAAAGTGATTGGCGCAGGAGTGGGCATGTAAGCTGGACCCAGCC
 AA
 -8520
 TCAGCATAACCAAATCCCTTGCCCACCCTGGGGAGGGTCCCTATAGTTGTTGCCAAGAGAGGCTCACCCC
 TG
 -8449
 TTCTCAAGAAGCTTACAACCTGGTAGGGGCAACAGGTTTTAATCTATCATTACACAAATATTTAATTTCA
 AT
 -8378
 ACTGTTGCAATAAGAGCTATGAAGGAAAAGAACTCCCCCTACTTTTACTTGGTGTAAAGATTTGAAG
 AA
 -8307
 GAAAAAAAAAAACACTGCCTGAAGGATTGTTATGGCCTTCTATATAATAGTGGCTGCAGACATTTGCC
 CA
 -8236
 TTATGTTTACAGCATGAACCCATGTGACAAATTCATCAAAGCGTTTGCCTAGGGAGAAAATTTGTATT
 AG
 -8165

 AGGAAGCACAGCAGTTTGGACTGAAAGACAAAGAAAATTCAGCCAATTCTGCTGATCTTTTTTGTATGGG
 GC
 -8094
 ACCTGGAAGCTGAAAGCTAAAGTGGTACTCAGGAACAGGGACTGCTACTTCTGTTCTGTTGATCCTG
 CC
 -8023
 CCAAACCTCCTCTCTCTGATTCCCTGATTCCACTGTGCCAGTGGGAATATATGCTCCCCAAGATGTCA
 AA
 -7952 **RS1160938 and v+ACTG(-7840)RS34916387**
 ACTAAAGGGAAATTGCAAAAAATATATACATATATTTTTAGAGAGAAAATAAGATTATAAAAAATGTGT
 TT
 -7881 **RS10689426 (-7842)+ACTG +ACTG(-7839)**
 TGTACCCCCAAGTTTCACTAAGAACTTCCCTGACTTCCAGGCCCTGGTTGTGCCCCACGCACCAGCCTG
 CC
 -7810 **(-7784)C RS254549 et RS1160938**
 CAGCTTTCCTGGACCAAACTTCCTAGCACCTAAGCAGGGGATGAGGGCAGATAAACTAAATCAGAAAAG
 GG
 -7739
 ATCTGTTCCCTCCTAGACTCAACCAACATGACCACCGTGGGGAAAGAAGAAACAAAAACAAGAGCAAAC
 CT
 -7668
 CTTAAAGAGCAGCCTGGCAGCTATCACCATTAGCATTAGCCCTCTGTCCACAGGACTCAGGACCAAA
 CC
 -7597
 CCTCACCTTCACTATCCCATCCGTTTCCCAAGAAGCAGAAATACTTATTCTCACATTTACAGATGGGG
 AA
 -7526 **(-7509)T RS254548**
 GCTGAGGCTAGGAGAGGTTATGTTATTTGCCAAAGCCACACAACCTAGTAAAAGCCACTGACAAGATTCT
 GG
 -7455
 CTCAGGCCATCAGGTGCCAGAGGCAGCATTTTTTGGCACCACAGGCCCTGCCTGGGAACAAGAGCATGC
 AG
 -7384
 AAAATCTCACAAGAGATGGGAACAAAATTTGGAAAATGCTAGCGTGCAGGGAGGGGGGAAGGTGTGAT
 TT
 -7313
 CCTGCTACAGACGCCAGAGTAAAAGCCACCCAGGAGTGCCTGTGCAGCCCTCCATAGTAAGGTCCAGC
 GG
 -7242



CTGCATTTATGCCCAAAGATGCCCTGGTGCTTGGAGTGAAGGAAGATTCCAGAGACAAGATTAGAAA
 CT
 -7171
 TCTCAGCTTAGCAGCTCTAGGGCTGGACCCGCCAACAAGCCATTTTACACATAAAGCAGTCAATGGGAG
 GG
 -7100
 GGTAGACGTAGGGGGCTAAACTCCCCACAGCACAGGGTCCAAGTTGGTAGACTGCACTTTCTCCAGGCG
 CA
 -7029
 GGTCCGCTAGTGCCGGCATCGGGGACTCGTTATCTTAACTTGGGACCCCTGGGTGCACAGAGCCCTGCAC
 AC
 -6958
 ACCACTGGAGAGGGGTTCCTGCTGTGAGGGTTGAGAGGAGGGTATGGAGTCCCTGGAACAGCAGCAGACA
 GG
 -6887
 GTGCAGAGGCCACCTGGCAGGGCCTGAACACCGAGGCCTCTGTGAGCTTGGGTGGGGCCGGCTTCCCGC
 TT
 -6816
 CGGAGGTTGGGGAGGGGTCGTGGGTCTCTGCGTTCCCAGGCCAAGCGGCCCTGGAGGCACGGACTAGC
 AG
 -6745
 GACGCCGAGGTGGCGGGGTCGCGGCCTCTCCCGCAGCAGCTGTGCGCGAGAACCAGGCAGGGAGGCGC
 CG
 -6674
 CTGCTGACTGCATCTCATGAAAGATTGAGCCCGGCTGCCGCGCTGCCATCTCCCGGCACCTTGGCGCG
 GA
 -6603
 AACGGTCGCTTGGAGCCCGTGGCCGTCGCGGGGCGAGGCTTAGCCGCTCCAGTCCCTGAGAAAGGCAGG
 CC
 -6532
 ACAGCCCGACCTGCCCTGTGGTCCCATCCCATAAATCCCAACAGCAAGCAGGCTCAGGCTGGGCACCTTCG
 GG
 -6461
 GTACCAGGAGTAGGTTGGCCAACTGGTTTCCACCATGAGGCTTCGCGCACAGGGTTATCTGGCCACGA
 GG
 -6390 **RS10069440 (-6345) C** **RS2431148 (-6322) G**
 CAACGCTGGGGAGCCCTGTGGCTGAGGGTGGGCAAAGGACAGGCTCCAGTTCCTTGGCTCCAGCCC
 GT
 -6319
 CTCCAGCGGCAGCCAGCCAGGAACGGCCTGCGGGGCCACAGGGTGGAGGCGTCACCGTTCGCAGGCC
 CG
 -6248
 CAGCAGGATGGTCGCTGGGGGATGTCAGGCATAGGGTTGGACAAGGGGGCCAGAAAGTGTCTGTCTCT
 GA
 -6177
 GGGGTTGGTGTGCCCTTTCCTCACCAGCCCAGCCCCTGAGGAGAGGGAAGAAGGCAATTCCCCCAACCA
 GG
 -6106
 GCAGGTGCGGGCGGTTGCCCCACCCTAACACCCCCTACCCCCAACACAGAAAACCTGGGGTCTGTCTCTC
 AA
 -6035
 ACCTCCCTGGCTGCCACGCTCTGGGCAGCGGACTCTCCCTGCCAACACGCAAGACCAGCTCCCTCCCGC
 AG
 -5964
 GCTGAGCAGAAAGAAGAAAGGTCCAATCTCAAAACCCCAAACCTCGACCACCAGCCCCGTCTAAACGGA
 AG
 -5893
 TAGGGCCAGCCCTCACGAGTCAGGTGGGAAACTGGGCCAGGGAGAGAAAGTGCCCCAGGGCCAGGCT
 GG
 -5822



-2982
 TCACATAGCACAGCTGGGGGAACACAAAGCCTCTGCTTACTCCTGAAAGAGTGCTGTTTTCTGTCTGT
 AT
 -2911
 GTGTGACG**T**GTCTGTGAGCGTGCAAGAAGCCCCTATCTTGACTGGGACAATGGCCAGTGAGTGTAGCTG
 GG
 -2840 **T(-2833) RS13170582**
 GAAGAATTGAGAGCATGTCCAGGTCCCTTCCCCAGCCAACGCCCAAGATCAGGCCACAGCCTCCTCACA
 AT
 -2769
 CAATTGCCCTCCTCACTCCTTGATCACTCAGTGCTGCCAGGCCAGCAGAACAGACTCTGCCAGCAGGC
 CC
G(-2697) RS31198
 CACTAGCCCCAGCTCCTCTTTGGGTCTCAGGTCCCCTGAGGATATGGGGCTTACCTGAAATGGTCTGA
 GG
 -2627
 GCTTTTCCCTTCTACACAGCAGGCATCAAGATCACCAAATAAAGGGACTATGTGCCTGCCTGGAGCCCT
 GC
 -2556 **RS35878427 (-2515) ACTG**
 CAGAGGTTTGGGCCAGAGGGGCACACAGCAGGTGCTCAATAACTGCATTAATGCACTAACAGTGAGG
 AA
 -2485
 ACACGCCCTCAGACTAAGCACTGAGTGCTGCTCACAGAATAGTCCCATTGGGGGATGGCCCAAAGAG
 TC
G(-2412) RS10079987
 ACTTTGGTCCCTCTGGGAAGTGAGAAGGCAAGTGAGAAGGCTGTGAGTCTTAACCTCCTCTAGAGGCC
 AC
 -2343 **RS35112921 ACTG (-2298)**
 AGACAGACCATTCAATTTCTAAGTCTCTACCCAGAGACGCACTGTGCTTCCCACCTTGGCCTGACATGTG
 GC
 -2272
 AGGGTTAGAACACACCTCCTATCCCCTGCCAGCCCGGTTTCATGCCAAGTAGCACATATATGCCATAAAC
 TC
 -2201

 AGCACTTCCATAGTGCACTGAATACATGTGTGTGTACAGCATCTCCGCATGGATGTACAGGATGTGTGT
 GT
 -2130
 GTGTGCGTGCCCCATGCTGTCTGCATTCAGGCTGTTCTTTTTGGTAAGACAGCTAAAAAAGAATGGT
 CT
 -2059 **RS11960693 (-1999) G**
 GTGAAGGGACTCCCTAGCACGCTGCAACACCTGAATATCTCCTTGAAAGGAGGGATCTTCTACTGCA
 GG
 -1988
 AGACTCGTGGTAAAGGTGGCCAAGAAACATGGCAACGGTGGGGCTGAGGGCAAATGCTGGGCAACTGTG
 CT
 -1917 **(-1882)A RS39882**
 TCCCCTATGTTCCCCTCCCCTAGCCAAGACTCATTTCATGGAGGGAGATCTCAGCTTGAAGAAGGCAG
 GA
 -1846
 GTCCTGAGCCTCCCAATCCAAACCCCTGAGAAGTGTCTCCCTCTGGCCTCAGACCCTGCATCCTGT
 GG
 -1775
 TCACAGACCCACAGTGAGAAAGGACCAGGCCCTAAGGAGCTGTGCTGTCTCTCCACGGCCAGAGCGGG
 GG
 -1704 **(-1648)A RS10070243**
 ATGGGGATGGGGATGGGGATGGGGATGGGGATGGGGATGGGGGTAGGGGTGGGGGTGCTTTGGACTAAC
 GT
 -1633 **ACTG (-1620) RS34114332**
 GGAGGGAATGGAAGGCAGGCCTGGTTCCACCTGCATGCCCCACCTGGCCCCAGCAGCCCCACAAGG
 AG

PP3



GAAGGTGGCTGCGGAGGGGGAGGGCGCGGGCGAGGCAGGGAGGGAGGGAGGGCGGCAGTGAGGGCGCGG
CG
-142
GCGCGGGCGGCTTGGGGCTGGATTCCGCCCGCGCTCCCTCGCTCGCTCGCTCCCTCCCCAGCCCCCTCC
CA
-71
-1

Figure 2

1 cccaggccca ccccacccag caccocctggc gcagggactg ctggaacctg
gctgtgcgcg
61 ctgtcgcttt aagacagact ctgccggcgc cgtccggagc cttagaaacc
ggccccgat
121 cgcgagccgg agccggagcc ggagccgggg ccggccgggc tgctgaggec
cgagcggcag
181 gagcgcagcg cggagcgtg agccaggcgc ccagtccgca gaagctgccg
ccgcctctgc
241 cgcgccggcg ccgcagcccc gggcggtcca tggggcgggc acggcgtcgc
tgcagcgcgc
301 ggcagccctg gagggcagcc gcttaggcgc tgcgtctttg tccccgagg
tcgcagccag
361 ggcggcgggg cgcgcccagc cccggcccct ggagcggccc ccgcggtccc
cacctccatg
421 gacgccttca aggggggcat gagcctggag cggctgcggg aggggctccg
gccgcgcggc
481 cgcgcccccc atgacatggg gcccgccttc cacctggccc ggcccccgca
ccccgcgag
541 ccgctcgaga actccgccag cgagtctgt gacacggagc tgccagagaa
ggagcgcggc
601 ggggaaccca aggggcccca ggacagtggg gcgggaggca cgggctgcgg
cggcgcagac
661 gaccagcca agaagaagaa gcagcggcgg caacgtacgc acttcacaag
ccagcagttg
721 caagagctag aggccacggt ccagaggaac cgtaaccccg acatgagcat
gagggaggag
781 atcgccgtgt ggaccaacct caccgagccg cgcgtgcggg tctggttcaa
gaaccggcga
841 gccaagtggc gtaagcgcga gcgtaaccag cagctggacc tgtgcaaggg
tggctacgtg
901 ccgcagttca gcgccctagt gcagccctac gaggacgtgt acgccgcggg
ctactctac
961 aacaactggg ccgccaagag cctggcgcca gcgccgtct ccaccaagag
cttcaccttc
1021 ttcaactcca tgagcccgt gtcgtcgcag tccatgttct cagcaccag
ctccatctcc
1081 tccatgacca tgccgtccag catgggcca ggcgcctg ctggcatgcc
caactcgggc
1141 ctcaacaaca tcaacaacct caccggctcc tcgctcaact cggccatgtc
gccgggcgct
1201 tgcccgtacg gcactcccgc ctcgcctac agcgtctacc gggacacgtg
caactcgagc
1261 ctagccagcc tgccgctcaa gtccaaacag cactcgtcgt ttggctacgg
cgccctgcag
1321 ggcccggcct cgggcctcaa cgcgtgccag tacaacagct gaccgcccgg
cgcaccacg
1381 cgggccggcg gccggagcgg ggaagggcgc gggcgaggag gacgcacgcg
gggccccggc
1441 tcgcaagccc cagctcaccg cgccgcggac ctcacacctg cgcagcccc
tcctcccact
1501 tcccactccg ggttggtttt gtgtttgctt ttccggaacc cactctgcc
tccaaaaaga
1561 caaaaaaaaa aaaaaaaaaa aaagcaaaaa gacgtcggag aaaagtgccg
cgaaaaaatg
1621 gatgagttgc aatttctctc gggatggcgc gggtggtgtg tgtgtgttcc
cacgggcccc
1681 ggaggcccac tccgcggagg gcacgcggcg cggtaggcga gcgccaggcc
ccagcggcgg
1741 ggggaggacg acctcgtatc ccgcgtcccc gccgcgtggg atccggactg
agtggccggg

```
1801 cctgcggaact ggatgtgcgg ggcttggaact tgcctaggat ttcccgaacc
cgtacaaaacc
1861 aagttgccct ctccgagcta ggcccggccg agagcgcctt agctcgagtc
ggatccgtgt
1921 tggggcgggc gttgggtttg gggggacggt gccccagcc caggatcggg
cactcagtgg
1981 agccgcacac ggccccggcg cgctggtag agcctcgtg gccccgcgc
ccggagccct
2041 atattaaggc cacggagcga cagcgggcag tgcgggcctg gcgggaggtg
ggggaggtcc
2101 atctcagaac accccagcct tgagottagc tgcaggccca ggccctctgc
tctgctcccg
2161 ggctaggagg tggccctctg tctgggcgaa cagccccctc ctcaccgcc
gccgtgcaag
2221 agtcgagccg gcagagcaag gggcgcggcc ccagggccct gcgcccactt
tgcacaccgg
2281 ctctccggcc cgcgcccctg tttacagcgt ccctgtgtat gttggactga
ctgtaataaa
2341 tctgtctata tcgactaaaa aaaaaaaaaa aaa
```

Figure 3

MDAFKGGMSLERLPEGLRPPPPPHDMGPAFHLARPADPREPLENSASESSDTELPEKERGGEPKGPED
SGAGGTGCGGADDPAKKKKQRRQORTHFTSQQLQELEATFQRNRYPDMSMREEIAVWTLNTEPRVRVWFK
NRRAKWRKRERNQQLDLCKGGYVPQFSGLVQPYEDVYAAGYSYNNWAAKSLAPAPLSTKSFTFFNSMSP
LSSQSMFSAPSSISSMTMPSSMGPGAVPGMPNSGLNNINNLTGSSLNSAMSPGACPYGTPASPYSVYRD
TCNSSLASLRLKSKQHSSFGYGALQGPASGLNACQYNS

Figure 4

**METHODS OF STRATIFYING ADOLESCENT
IDIOPATHIC SCOLIOSIS, ISOLATED
NUCLEIC ACID MOLECULES FOR USE IN
SAME AND KITS USING SAME**

CROSS REFERENCE TO RELATED
APPLICATIONS

[0001] This application claims priority, under 35 U.S.C. § 119(e), of U.S. provisional application Ser. No. 60/895,490, filed on Mar. 19, 2007, and of U.S. provisional application Ser. No. 60/908,417, filed on Mar. 28, 2007. The contents of the above documents are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

[0002] The present invention relates methods of stratifying adolescent idiopathic scoliosis, isolated nucleic acid molecules for use in same and kits using same.

BACKGROUND OF THE INVENTION

[0003] Spinal deformities and scoliosis in particular, represent the most prevalent type of orthopaedic deformities in children and adolescents (0.2-6% of the population). Published studies suggest that one percent to six percent of the population will develop scoliosis. This condition leads to the formation of severe deformities of the spine affecting mainly adolescent girls in number and severity.

[0004] At present, the cause of adolescent idiopathic scoliosis (AIS), remains unclear (Connor J M, Conner A N, Connor R A, Tolmie J L, Yeung B, Goudie D. Genetic aspects of early childhood scoliosis. *Am J Med Genet.* 1987;27:419-424; and Machida M. Cause of idiopathic scoliosis. *Spine.* 1999;24:2576-2583) and there remains a need to stratify children or adolescents having AIS, identify children or adolescents at risk of developing AIS and identify which of the affected individuals are at risk of progression.

[0005] It has been showed that Pitx1+/- mice developed severe spinal deformities after weaning. Paired-like homeodomain transcription factor 1 (Pitx1, previously called Ptx1) is a homeodomain transcription factor detected initially throughout pituitary development. The Pitx-family contains three related members, Pitx1, Pitx2 and Pitx3, which are members of the paired class of homeodomain proteins. The three Pitx factors have similar transcription properties (Drouin, J., Lanctôt, C., & Tremblay, J. J. La famille Ptx des facteurs de transcription à homéodomaine. *Médecine/Sciences* 14, 335-339 (1998); Drouin, J., Lamolet, B., Lamonerie, T., Lanctot, C., & Tremblay, J. J. The PTX family of homeodomain transcription factors during pituitary developments. *Mol. Cell Endocrinol.* 140, 31-(1998); and Lanctôt, C., Lamolet, B., & Drouin, J. The bicoid-related homeoprotein Ptx1 defines the most anterior domain of the embryo and differentiates posterior from anterior lateral mesoderm. *Development* 124, 2807-2817 (1997)). Among others, this transcription factor controls the development of craniofacial and hind limb specific structures in mammals. The pitx1 gene is highly expressed in mouse hind limb long bones during development and accumulation of high levels of Pitx1 proteins were detected by immunohistochemistry on hind limb long bone sections mainly in the periarticular region, along the perichondrium (including at the hip and knee joints) and also in the nuclei of proliferative chondrocytes (Lanctôt, C., Lamolet, B., & Drouin, J. The bicoid-related homeoprotein

Ptx1 defines the most anterior domain of the embryo and differentiates posterior from anterior lateral mesoderm. *Development* 124, 2807-2817 (1997)). Pitx1 expression was also detected in craniofacial structures such as the mandible and at the temporo-mandibular joints. It has been shown that targeted inactivation of the mouse pitx1 gene severely impairs craniofacial and hind limb development. While null mice died at birth, all PITX1+/- mice which are normal at birth, developed severe spinal deformities (100% starting at 2 months).

[0006] The present description refers to a number of documents, the content of which is herein incorporated by reference in their entirety.

SUMMARY OF THE INVENTION

[0007] In accordance with the present invention, there is provided a method of stratifying a subject having adolescent idiopathic scoliosis (AIS) comprising: providing a cell sample isolated from the subject; detecting Paired-like homeodomain transcription factor 1 (Pitx1) expression in the cell sample; whereby the results of the detecting step enables the stratification of the subject having AIS as belonging to an AIS subclass.

[0008] In accordance with another aspect of the present invention, there is provided a method of stratifying a subject having adolescent idiopathic scoliosis (AIS) for a clinical trial comprising: providing a cell sample isolated from the subject; detecting Paired-like homeodomain transcription factor 1 (Pitx1) expression in the cell sample; and stratifying the subject for a clinical trial based on the results of the detecting step.

[0009] In accordance with another aspect of the present invention, there is provided a method for predicting a risk for developing adolescent idiopathic scoliosis (AIS) in a subject comprising providing a cell sample isolated from the subject; and detecting Paired-like homeodomain transcription factor 1 (Pitx1) expression in the cell sample; wherein an absence of Pitx1 expression is indicative that the subject is at risk for developing AIS.

[0010] In a specific embodiment of these methods, an absence of Pitx1 expression is indicative that the subject is at risk for developing a Cobb's angle of 45° and above. In another specific embodiment, the detecting step is performed with an isolated nucleic acid molecules specific to a Pitx1 transcription product. In another specific embodiment, the isolated nucleic acid molecule is detectably labeled. In another specific embodiment, the detecting step is performed with an antibody that binds specifically to Pitx1. In another specific embodiment, the cell sample is selected from the group consisting of an osteoblasts sample, a chondrocytes sample, a skeletal myoblasts sample and a blood sample. In another specific embodiment, the cell sample is an osteoblasts sample. In another specific embodiment, the method further comprises a step of selecting a preventive action or a treatment in light of the results of the detecting step. In another specific embodiment, said subject is pre-diagnosed as being a likely candidate for developing adolescent idiopathic scoliosis.

[0011] In accordance with another aspect of the present invention, there is provided a method of selecting a compound potentially useful in the treatment of adolescent idiopathic scoliosis, said method comprising the steps of (a) contacting a test compound with at least one cell known to express Paired-like homeodomain transcription factor 1 (Pitx1); and (b) determining Pitx1 expression level; wherein

the test compound is selected if Pitx1 expression level is increased in the presence of the test compound as compared to that in the absence thereof.

[0012] In a specific embodiment, said cell is an osteoblast. In another specific embodiment, said cell is from a subject having adolescent idiopathic scoliosis (AIS). In another specific embodiment, the subject is a human.

[0013] In accordance with another aspect of the present invention, there is provided kit comprising an isolated nucleic acid molecule specific to a transcription product of a Paired-like homeodomain transcription factor 1 (Pitx1) and instructions to use the probe to predict whether a subject is at risk for developing adolescent idiopathic scoliosis.

[0014] In accordance with another aspect of the present invention, there is provided kit comprising an isolated nucleic acid molecule specific to a transcription product of a Paired-like homeodomain transcription factor 1 (Pitx1) and instructions to use the probe to stratify a subject having adolescent idiopathic scoliosis.

[0015] In another specific embodiment, the kit further comprises a container for a nucleotide sample from the subject.

[0016] In accordance with another aspect of the present invention, there is provided kit comprising an antibody specific to a Paired-like homeodomain transcription factor 1 (Pitx1) and instructions to use the antibody to predict whether a subject is at risk for developing adolescent idiopathic scoliosis.

[0017] In accordance with another aspect of the present invention, there is provided kit comprising an antibody specific to a Paired-like homeodomain transcription factor 1 (Pitx1) and instructions to use the antibody to stratify a subject having adolescent idiopathic scoliosis.

[0018] The articles “a,” “an” and “the” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article.

[0019] The term “including” and “comprising” are used herein to mean, and re used interchangeably with, the phrases “including but not limited to” and “comprising but not limited to”.

[0020] The terms “such as” are used herein to mean, and is used interchangeably with, the phrase “such as but not limited to”.

[0021] As used herein the terms “likely candidate for developing adolescent idiopathic scoliosis” include children of which a least one parent has adolescent idiopathic scoliosis. Among other factors, age (adolescence), gender and other family antecedent are factors that are known to contribute to the risk of developing a scoliosis and are used to a certain degree to assess the risk of developing AIS. In certain subjects, scoliosis develops rapidly over a short period of time to the point of requiring a corrective surgery (often when the deformity reaches a Cobb’s angle $\geq 50^\circ$). Current courses of action available from the moment AIS is diagnosed (when scoliosis is apparent) include observation (when Cobb’s angle is around)10-25°, orthopaedic devices (when Cobb’s angle is around 25-30°), and surgery (over 45°). A more reliable determination of the risk of progression could enable to 1) select an appropriate diet to remove certain food products identified as contributors to scoliosis; 2) select the best therapeutic agent; and/or 3) select the least invasive available treatment such as postural exercises, orthopaedic device, or less invasive surgeries or surgeries without fusions (a surgery that does not fuse vertebra and preserves column mobility). The present invention encompasses selecting the most effi-

cient and least invasive known preventive actions or treatments in view of the determined risk of developing AIS. The present invention also encompasses stratifying AIS patients with methods of the present invention.

[0022] As used herein, the terms “severe AIS” refers to a scoliosis characterized by Cobb’s angle of 45° or more.

[0023] As used herein, the term “Pitx1 expression” is used to refer Pitx1 transcription and/or Pitx1 translation. In a more specific embodiment, Pitx1 expression refers to Pitx1 transcription.

[0024] As used herein the terms “risk of developing AIS” and “risk of progression of AIS” are used interchangeably and refer to a genetic or metabolic predisposition of a subject to develop a scoliosis (i.e. spinal deformity) and/or a more severe scoliosis at a future time.

[0025] As used herein the term “subject” is meant to refer to any mammal including human, mice, rat, dog, cat, pig, monkey, horse, etc. In a particular embodiment, it refers to a human. In an other particular embodiment, it refers to a horse and more specifically a racing horse.

[0026] As used herein the terms “blood sample” is whole blood and it is a cell sample in that it comprises peripheral blood mononuclear cells.

[0027] Without being so limited, cells where Pitx1 is known to be expressed include cells from muscles, bone and cartilages such as osteoblasts, chondrocytes and skeletal myoblasts.

[0028] The present invention also relates to methods for the determination of the level of expression of transcripts or translation product of a single gene such as pitx1. The present invention therefore encompasses any known method for such determination including real time PCR and competitive PCR, Northern blots, nuclease protection, plaque hybridization and slot blots.

[0029] The present invention also concerns isolated nucleic acid molecules including probes and primers to detect Pitx1. In specific embodiments, the isolated nucleic acid molecules have no more than 300, or no more than 200, or no more than 100, or no more than 90, or no more than 80, or no more than 70, or no more than 60, or no more than 50, or no more than 40 or no more than 30 nucleotides. In specific embodiments, the isolated nucleic acid molecules have at least 17, or at least 18, or at least 19, or at least 20, or at least 30, or at least 40 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 20 and no more than 300 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 20 and no more than 200 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 20 and no more than 100 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 20 and no more than 90 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 20 and no more than 80 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 20 and no more than 70 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 20 and no more than 60 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 20 and no more than 50 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 20 and no more than 40 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 17 and no more than 40 nucleotides. In other specific embodiments, the isolated

nucleic acid molecules have at least 20 and no more than 30 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 17 and no more than 30 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 30 and no more than 300 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 30 and no more than 200 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 30 and no more than 100 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 30 and no more than 90 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 30 and no more than 80 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 30 and no more than 70 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 30 and no more than 60 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 30 and no more than 50 nucleotides. In other specific embodiments, the isolated nucleic acid molecules have at least 30 and no more than 40 nucleotides. It should be understood that in real-time PCR, primers also constitute probe without the traditional meaning of this term. Primers or probes appropriate to detect Pitx1 in the methods of the present invention can be designed with known methods using sequences distributed across the Pitx1 nucleotide sequence. (Buck et al. Design Strategies and Performance of Custom DNA Sequencing primers. *Biotechniques* 27:528-536 (September 1999)).

[0030] Although amino acid and nucleotide sequences for Pitx1 are included herein, the present invention is not so limited and encompasses the detection of any Pitx1 protein or nucleotides isolated from a subject. Without being so limited, the present invention encompasses the detection of the Pitx1 presented in Table 1.

TABLE 1

ACCESSION NUMBERS FOR PITX1 SEQUENCES		
	Nucleotide	Protein
Genomic	AC004764.1	AAC17733.1
Genomic	AC008406.7 (17530..24049, complement)	None
Genomic	AF009648.1	AAB65251.1
Genomic	AF009649.1	AAB65251.1
Genomic	AF009650.1	AAB65251.1
Genomic	CH471062.2	EAW62226.1 EAW62227.1 CAJ86537.1 BAF83324.1
Genomic mRNA	CS278249.1	None
mRNA	AK290635.1	AAH03685.1
mRNA	AL578756.2	AAH09412.1
mRNA	BC003685.1	None
mRNA	BC009412.1	None
mRNA	BX362641.2	None
mRNA	CR601326.1	None
mRNA	CR603120.1	None
mRNA	CR610821.1	None
mRNA	U70370.1	AAC51126.1
Synthetic	EU446647.1	ABZ92176.1 P78337.2
mRNA	NM_002653 version NM_002653.4	NP_002644 version NP_002644.4
Chromosome 5, reference assembly, complete sequence	NC_000005(134391323- 134397863)	NC_000005.8

TABLE 1-continued

ACCESSION NUMBERS FOR PITX1 SEQUENCES		
	Nucleotide	Protein
Genomic	NC_000005.8 Reference assembly 134397863..134391323, complement	
Genomic	NT_034772.5 36784977..36778437, complement	
Genomic	AC_000048.1 130493751..130487209, complement	
Genomic	NW_922784.1 8121767..8115225, complement	
Genomic	AC_000137.1 91265592..91277386	
Genomic	NW_001838952.2 4413502..4425296	
Genomic	NW_001838952.2 4413502..4425296	

[0031] Probes of the invention can be utilized with naturally occurring sugar-phosphate backbones as well as modified backbones including phosphorothioates, dithionates, alkyl phosphonates and α -nucleotides and the like. Modified sugar-phosphate backbones are generally known (Miller, 1988. *Ann. Reports Med. Chem.* 23:295; Moran et al., 1987. *Nucleic Acids Res.*, 14:5019.). Probes of the invention can be constructed of either ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), and preferably of DNA.

[0032] The types of detection methods in which probes can be used include Southern blots (DNA detection), dot or slot blots (DNA, RNA), and Northern blots (RNA detection). Although less preferred, labeled proteins could also be used to detect a particular nucleic acid sequence to which it binds. Other detection methods include kits containing probes on a dipstick setup and the like.

[0033] As used herein the terms “detectably labeled” refer to a marking of a probe or antibody in accordance with the present invention that will allow the detection of the Pitx1 expression in methods and kits of the present invention. Although the present invention is not specifically dependent on the use of a label for the detection of a particular nucleic acid sequence, such a label might be beneficial, by increasing the sensitivity of the detection. Furthermore, it enables automation. Probes can be labeled according to numerous well known methods (Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). Non-limiting examples of labels include 3H, 14C, 32P, and 35S. Non-limiting examples of detectable markers include ligands, fluorophores, chemiluminescent agents, enzymes, and antibodies. Other detectable markers for use with probes, which can enable an increase in sensitivity of the method of the invention, include biotin and radionucleotides. It will become evident to the person of ordinary skill that the choice of a particular label dictates the manner in which it is bound to the probe or antibody.

[0034] As commonly known, radioactive nucleotides can be incorporated into probes of the invention by several methods. Non-limiting examples thereof include kinasing the 5' ends of the probes using gamma 32P ATP and polynucleotide kinase, using the Klenow fragment of Pol I of *E. coli* in the presence of radioactive dNTP (e.g. uniformly labeled DNA probe using random oligonucleotide primers in low-melt

gels), using the SP6/T7 system to transcribe a DNA segment in the presence of one or more radioactive NTP, and the like.

[0035] The present invention also relates to methods of selecting compounds. As used herein the term “compound” is meant to encompass natural, synthetic or semi-synthetic compounds, including without being so limited chemicals, macromolecules, cell or tissue extracts (from plants or animals), nucleic acid molecules, peptides, antibodies and proteins.

[0036] The present invention also relates to arrays. As used herein, an “array” is an intentionally created collection of molecules which can be prepared either synthetically or biosynthetically. The molecules in the array can be identical or different from each other. The array can assume a variety of formats, e.g., libraries of soluble molecules; libraries of compounds tethered to resin beads, silica chips, or other solid supports.

[0037] As used herein “array of nucleic acid molecules” is an intentionally created collection of nucleic acids which can be prepared either synthetically or biosynthetically in a variety of different formats (e.g., libraries of soluble molecules; and libraries of oligonucleotides tethered to resin beads, silica chips, or other solid supports). Additionally, the term “array” is meant to include those libraries of nucleic acids which can be prepared by spotting nucleic acids of essentially any length (e.g., from 1 to about 1000 nucleotide monomers in length) onto a substrate. The term “nucleic acid” as used herein refers to a polymeric form of nucleotides of any length, either ribonucleotides, deoxyribonucleotides or peptide nucleic acids (PNAs), that comprise purine and pyrimidine bases, or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases. The backbone of the polynucleotide can comprise sugars and phosphate groups, as may typically be found in RNA or DNA, or modified or substituted sugar or phosphate groups. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. The sequence of nucleotides may be interrupted by non-nucleotide components. Thus the terms nucleoside, nucleotide, deoxynucleoside and deoxynucleotide generally include analogs such as those described herein. These analogs are those molecules having some structural features in common with a naturally occurring nucleoside or nucleotide such that when incorporated into a nucleic acid or oligonucleotide sequence, they allow hybridization with a naturally occurring nucleic acid sequence in solution. Typically, these analogs are derived from naturally occurring nucleosides and nucleotides by replacing and/or modifying the base, the ribose or the phosphodiester moiety. The changes can be tailor made to stabilize or destabilize hybrid formation or enhance the specificity of hybridization with a complementary nucleic acid sequence as desired.

[0038] As used herein “solid support”, “support”, and “substrate” are used interchangeably and refer to a material or group of materials having a rigid or semi-rigid surface or surfaces. In many embodiments, at least one surface of the solid support will be substantially flat, although in some embodiments it may be desirable to physically separate synthesis regions for different compounds with, for example, wells, raised regions, pins, etched trenches, or the like. According to other embodiments, the solid support(s) will take the form of beads, resins, gels, microspheres, or other geometric configurations.

[0039] Any known nucleic acid arrays can be used in accordance with the present invention. For instance, such arrays

include those based on short or longer oligonucleotide probes or primers as well as cDNAs or polymerase chain reaction (PCR) products (Lyons P., 2003. Advances in spotted microarray resources for expression profiling. Briefings in Functional Genomics and Proteomics 2, 21-30). Other methods include serial analysis of gene expression (SAGE), differential display, (Ding G. and Cantor C. R., 2004. Quantitative analysis of nucleic acids—the last few years of progress. J Biochem Biol 37, 1-10) as well as subtractive hybridization methods (Scheel J., Von Brevern M. C., Horlein A., Fisher A., Schneider A., Bach A. 2002. Yellow pages to the transcriptome. Pharmacogenomics 3, 791-807), differential screening (DS), RNA arbitrarily primer (RAP)-PCR, restriction endonucleolytic analysis of differentially expressed sequences (READS), amplified restriction fragment-length polymorphisms (AFLP).

[0040] “Stringent hybridization conditions” and “stringent hybridization wash conditions” in the context of nucleic acid hybridization experiments such as Southern and Northern hybridization are sequence dependent, and are different under different environmental parameters. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids, the T_m can be approximated from the equation of Meinkoth and Wahl, 1984; $T_m = 81.5^\circ \text{C.} + 16.6 (\log M) + 0.41 (\% \text{GC}) - 0.61 (\% \text{form}) - 500/L$; where M is the molarity of monovalent cations, % GC is the percentage of guanosine and cytosine nucleotides in the DNA, % form is the percentage of formamide in the hybridization solution, and L is the length of the hybrid in base pairs. T_m is reduced by about 1°C. for each 1% of mismatching; thus, T_m , hybridization, and/or wash conditions can be adjusted to hybridize to sequences of the desired identity. For example, if sequences with >90% identity are sought, the T_m can be decreased 10°C. Generally, stringent conditions are selected to be about 5°C. lower than the thermal melting point I for the specific sequence and its complement at a defined ionic strength and pH. However, severely stringent conditions can utilize a hybridization and/or wash at 1, 2, 3, or 4°C. lower than the thermal melting point I; moderately stringent conditions can utilize a hybridization and/or wash at 6, 7, 8, 9, or 10°C. lower than the thermal melting point I; low stringency conditions can utilize a hybridization and/or wash at 11, 12, 13, 14, 15, or 20°C. lower than the thermal melting point I. Using the equation, hybridization and wash compositions, and desired T, those of ordinary skill will understand that variations in the stringency of hybridization and/or wash solutions are inherently described. If the desired degree of mismatching results in a T of less than 45°C. (aqueous solution) or 32°C. (formamide solution), it is preferred to increase the SSC concentration so that a higher temperature can be used. An extensive guide to the hybridization of nucleic acids is found in Tijssen, 1993. Generally, highly stringent hybridization and wash conditions are selected to be about 5°C. lower than the thermal melting point T_m for the specific sequence at a defined ionic strength and pH.

[0041] An example of highly stringent wash conditions is 0.15 M NaCl at 72°C. for about 15 minutes. An example of stringent wash conditions is a $0.2\times$ SSC wash at 65°C. for 15 minutes (see Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). *Molecular Cloning: A Laboratory Manual*, Cold

Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. for a description of SSC buffer). Often, a high stringency wash is preceded by a low stringency wash to remove background probe signal. An example medium stringency wash for a duplex of, e.g., more than 100 nucleotides, is 1× SSC at 45° C. for 15 minutes. An example low stringency wash for a duplex of, e.g., more than 100 nucleotides, is 4-6× SSC at 40° C. for 15 minutes. For short probes (e.g., about 10 to 50 nucleotides), stringent conditions typically involve salt concentrations of less than about 1.5 M, more preferably about 0.01 to 1.0 M, Na ion concentration (or other salts) at pH 7.0 to 8.3, and the temperature is typically at least about 30° C. and at least about 60° C. for long robes (e.g., >50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. In general, a signal to noise ratio of 2× (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization. Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the proteins that they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.

[0042] Very stringent conditions are selected to be equal to the T_m for a particular probe. An example of stringent conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on a filter in a Southern or Northern blot is 50% formamide, e.g., hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37° C., and a wash in 0.1× SSC at 60 to 65° C. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulphate) at 37° C., and a wash in 1× to 2× SSC (20× SSC=3.0 M NaCl/0.3 M trisodium citrate) at 50 to 55° C. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1.0 M NaCl, 1% SDS at 37° C., and a wash in 0.5× to 1× SSC at 55 to 60° C.

[0043] Washing with a solution containing tetramethylammonium chloride (TeMAC) could allow the detection of a single mismatch using oligonucleotide hybridization since such mismatch could generate a 10° C. difference in the annealing temperature. The formulation to determine the washing temperature is $T_m (^{\circ}C.) = -682 (L^{-1}) + 97$ where L represents the length of the oligonucleotide that will be used for the hybridization.

[0044] The present invention relates to a kit for stratify AIS and/or predicting whether a subject is at risk of developing AIS comprising an isolated nucleic acid, a protein or a ligand such as an antibody in accordance with the present invention. For example, a compartmentalized kit in accordance with the present invention includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers or strips of plastic or paper. Such containers allow the efficient transfer of reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the subject sample (DNA genomic nucleic acid, cell sample or blood samples), a container which contains in some kits of the present invention, the probes used in the methods of the present invention, containers which contain enzymes, containers which contain wash reagents, and containers which

contain the reagents used to detect the extension products. Kits of the present invention may also contain instructions to use these probes and or antibodies to stratify AIS or predict whether a subject is at risk of developing AIS.

[0045] As used herein, the term “purified” in the expression “purified antibody” is simply meant to distinguish man-made antibody from an antibody that may naturally be produced by an animal against its own antigens. Hence, raw serum and hybridoma culture medium containing anti-Pitx1 antibody are “purified antibodies” within the meaning of the present invention.

[0046] As used herein, the term “ligand” broadly refers to natural, synthetic or semi-synthetic molecules. The term “molecule” therefore denotes for example chemicals, macromolecules, cell or tissue extracts (from plants or animals) and the like. Non limiting examples of molecules include nucleic acid molecules, peptides, antibodies, carbohydrates and pharmaceutical agents. The ligand appropriate for the present invention can be selected and screened by a variety of means including random screening, rational selection and by rational design using for example protein or ligand modeling methods such as computer modeling. The terms “rationally selected” or “rationally designed” are meant to define compounds which have been chosen based on the configuration of interacting domains of the present invention. As will be understood by the person of ordinary skill, macromolecules having non-naturally occurring modifications are also within the scope of the term “ligand”. For example, peptidomimetics, well known in the pharmaceutical industry and generally referred to as peptide analogs can be generated by modeling as mentioned above.

Antibodies

[0047] Both monoclonal and polyclonal antibodies directed to Pitx1 are included within the scope of this invention as they can be produced by well established procedures known to those of skill in the art. Additionally, any secondary antibodies, either monoclonal or polyclonal, directed to the first antibodies would also be included within the scope of this invention.

[0048] As used herein, the term “anti-Pitx1 antibody” or “immunologically specific anti-Pitx1 antibody” refers to an antibody that specifically binds to (interacts with) a Pitx1 protein and displays no substantial binding to other naturally occurring proteins other than the ones sharing the same antigenic determinants as the Pitx1 protein. The term antibody or immunoglobulin is used in the broadest sense, and covers monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies, and antibody fragments so long as they exhibit the desired biological activity. Antibody fragments comprise a portion of a full length antibody, generally an antigen binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab')₂, and Fv fragments, diabodies, linear antibodies, single-chain antibody molecules, single domain antibodies (e.g., from camelids), shark NAR single domain antibodies, and multispecific antibodies formed from antibody fragments. Antibody fragments can also refer to binding moieties comprising CDRs or antigen binding domains including, but not limited to, VH regions (V_H, V_H-V_H), anticalins, PepBodies™, antibody-T-cell epitope fusions (Troybodies) or Peptibodies. Additionally, any secondary antibodies, either monoclonal or polyclonal, directed to the first antibodies would also be included within the scope of this invention.

[0049] In general, techniques for preparing antibodies (including monoclonal antibodies and hybridomas) and for detecting antigens using antibodies are well known in the art (Campbell, 1984, In "Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology", Elsevier Science Publisher, Amsterdam, The Netherlands) and in Harlow et al., 1988 (in: Antibody A Laboratory Manual, CSH Laboratories). The term antibody encompasses herein polyclonal, monoclonal antibodies and antibody variants such as single-chain antibodies, humanized antibodies, chimeric antibodies and immunologically active fragments of antibodies (e.g. Fab and Fab' fragments) which inhibit or neutralize their respective interaction domains in Hyphen and/or are specific thereto.

[0050] Polyclonal antibodies are preferably raised in animals by multiple subcutaneous (sc), intravenous (iv) or intraperitoneal (ip) injections of the relevant antigen with or without an adjuvant. It may be useful to conjugate the relevant antigen to a protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl_2 , or $\text{R}^1\text{N}=\text{C}=\text{NR}$, where R and R^1 are different alkyl groups.

[0051] Animals may be immunized against the antigen, immunogenic conjugates, or derivatives by combining the antigen or conjugate (e.g., 100 μg for rabbits or 5 μg for mice) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with the antigen or conjugate (e.g., with $\frac{1}{2}$ to $\frac{1}{10}$ of the original amount used to immunize) in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. Preferably, for conjugate immunizations, the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response.

[0052] Monoclonal antibodies may be made using the hybridoma method first described by Kohler et al., *Nature*, 256:495 (1975), or may be made by recombinant DNA methods (e.g., U.S. Pat. No. 6,204,023). Monoclonal antibodies may also be made using the techniques described in U.S. Pat. No. 6,025,155 and U.S. Pat. No. 6,077,677 as well as U.S. Patent Application Publication Nos. 2002/0160970 and 2003/0083293 (see also, e.g., Lindenbaum et al., 2004).

[0053] In the hybridoma method, a mouse or other appropriate host animal, such as a rat, hamster or monkey, is immunized (e.g., as hereinabove described) to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the antigen used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell.

[0054] The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the

parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.

[0055] Other objects, advantages and features of the present invention will become more apparent upon reading of the following non-restrictive description of specific embodiments thereof, given by way of example only with reference to the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

[0056] In the appended drawings:

[0057] FIG. 1 compares Pitx1 expression in osteoblasts from severely affected AIS patients and matched control subjects. Reverse transcription-polymerase chain reaction for pitx1 gene expression in human osteoblasts of control subjects (n=46) and patients with AIS (n=29). Pitx1 specific mRNA transcripts were detected in the control tissue. Loss of the pitx1 gene expression was observed in all examined AIS samples and β -actin expression was used as internal control;

[0058] FIG. 2 shows the sequence of a 10 kb pitx1 promoter region (SEQ ID NO: 1) and polymorphisms in that pitx1 promoter region between human subjects. The primers used to cover the different amplicons covering the 10 kb regions are provided in Table 4 below;

[0059] FIG. 3 shows the sequence of the Pitx1 mRNA (SEQ ID NO: 2) (NM_002653); and

[0060] FIG. 4 shows the Pitx1 amino acid sequence (SEQ ID NO: 3) (NP_002644).

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

[0061] The present invention demonstrated by RT-PCR analysis a loss of pitx1 gene expression in osteoblasts derived from biopsies obtained intraoperatively of severely affected AIS patients (n=46) while osteoblasts derived from non-scoliotic patients (trauma cases) still expressed Pitx1 (n=29).

[0062] The present invention is illustrated in further details by the following non-limiting examples.

Human Specimens

[0063] Informed consent was obtained from all study participants as approved by each individual and collective institutional Review Board (Ste-Justine University Hospital, Montreal's Children Hospital and The Shriners Hospital for Children all located in Montreal). All individuals were screened through a series of steps including history and clinical data, assuring the idiopathic nature of the problem. This was followed by a review of spinal radiographs. A person was deemed to be affected by AIS if history and physical examination were consistent with the diagnosis of idiopathic scoliosis and a minimum of a ten degree curvature in the coronal plane with vertebral rotation was found on the radiograph. Participants will also be screened as to the potential familial distribution of the disorder on a case by case basis. In the event that the disorder is found to be familial, family members will undergo parallel screening for the presence or absence of the condition. Other patients (without scoliosis) visiting our trauma clinics were used as controls.

[0064] The clinical characteristics of the examined AIS and control subjects are shown in Table 2 and Table 3 respectively. Scoliotic patients with a diagnostic other than AIS were tested as control subjects.

TABLE 2

CLINICAL CHARACTERISTIC OF EXAMINED AIS SUBJECTS					
Number	GeN/Aer	Age	Curve type	Cobb angle	Heredity
1006	f	12, 65	double major	61-46	No
1007	m	18, 67	right thoracic	61	Yes
1045	f	19, 48	thoracolumbar left	38	No
1066	f	17, 33	thoracolumbar right thoracic	53	Yes
1137	f	20, 54	double major	65-42	No
1167	m	14, 58	left thoracic	49	No
1263	f	13, 32	double major	53	No
1266	m	15, 56	double major	52	No
1274	f	13, 27	double major	42	No
1276	f	15, 26	left thoracic	42	No
1277	f	12, 73	double major	57-48	No
1280	f	14, 4	double major	56-46	No
1294	f	16, 92	left thoracic	N/A	Yes
1306	f	13, 15	double major	77-48	Yes
1308	f	15, 3	double major	77-20	No
1310	f	15, 52	double major	55-42	No
1311	f	14, 6	double major	78	Yes
1315	f	14, 62	right thoracic	91	No
1317	f	13, 97	right thoracic	53	Yes
1318	f	13, 7	left thoracic	49	No
1322	f	13, 11	thoracolumbar double major	51	No
1325	f	16, 16	left thoracic	44	Yes
1329	m	14, 02	right thoracic	61	Yes
1335	f	17, 6	thoracolumbar double major	47-50	No
1337	f	14, 13	double major	57-48	Yes
1339	f	14, 28	right thoracic	31	No
1346	f	13, 54	double major	50-34	Yes
1347	f	18, 55	double major	56-45	No
1349	f	11, 69	left thoracic	74	No
1352	f	7, 8	thoracolumbar right thoracic	51	No
1360	f	9, 92	double major	53-46	Yes
1385	f	16, 06	double major	42-23	No
1390	f	15, 61	left thoracic	53	No
1391	f	15, 01	thoracolumbar left lumbar	54	No
1395	f	17, 79	left thoracic	84	Yes
1402	f	15, 82	thoracolumbar right thoracic	51	No
1406	f	14, 89	double major	62-60	No
1409	f	13, 62	right thoracic	40	No
1410	f	13, 73	right thoracic	56	Yes
1417	f	13, 24	right thoracic	59	Yes
1418	f	13, 08	right thoracic	41	No
1420	f	13, 42	double major	60-48	Yes
1422	f	12, 44	double major	60-50	Yes
1425	f	13, 42	right thoracic	68	Yes
1439	f	N/A	right thoracic	69	Yes
1442	f	N/A	right thoracic	60	No

N/A: not available

TABLE 3

CLINICAL CHARACTERISTICS OF EXAMINED CONTROL SUBJECTS						
Number	Gender	Age	Health status	Curve type	Cobb angle	Heredity
C100	f	N/A	healthy	nd	nd	No
C101	N/A	N/A	healthy	nd	nd	No
C102	f	18	healthy	nd	nd	No
C103	N/A	N/A	healthy	nd	nd	No
C104	f	14	healthy	nd	nd	No
C105	f	11	healthy	nd	nd	No
C106	m	12	healthy	nd	nd	No
C107	f	13	healthy	nd	nd	No
C108	f	12	healthy	nd	nd	No
C109	m	14	healthy	nd	nd	No
C110	m	15	healthy	nd	nd	No
c111	m	14	healthy	nd	nd	No
C112	f	11	healthy	nd	nd	No
C113	m	14	healthy	nd	nd	No
C114	N/A	N/A	healthy	nd	nd	No
C115	m	17	healthy	nd	nd	No
C116	m	12	healthy	nd	nd	No
C117	m	16	healthy	nd	nd	No
C118	m	12	healthy	nd	nd	No
C119	f	15	healthy	nd	nd	No
C120	f	15	healthy	nd	nd	No
C121	f	8	healthy	nd	nd	No
1285	f	15, 87	paralytic scoliosis	N/A	72	Yes
1293	m	11, 79	congenital scoliosis	left lumbar	38	No
1341	f	11, 14	congenital scoliosis	double major	61-65	No
1375	f	13, 71	congenital scoliosis	right thoracolumbar	53	Yes
1431	m	19, 13	neurological scoliosis	double major	90-90	No
1434	f	12, 43	congenital scoliosis	double major	79-77	No
1436	f	13, 93	kypho-scoliosis	kyphosis	120	No

N/A: not available and nd: not detected

Osteoblasts Cultures

[0065] Osteoblasts were obtained from bone specimens taken intraoperatively during spine surgeries of AIS patients and trauma surgeries in the case of control subjects. This cell type was chosen as cellular model for this study as described previously (Rodriguez M M, Ron D, Touhara K, Chen C H, Mochly-Rosen D. RACK1, a protein kinase C anchoring protein, coordinates the binding of activated protein kinase C and select pleckstrin homology domains in vitro. *Biochemistry*. 1999;38:13787-13794).

Isolation of Human Osteoblasts

[0066] In all cases, osteoblasts were obtained intraoperatively from bone specimens originating from vertebrae (varying from T3 to L4 according to the surgical procedure performed). Bony fragments were mechanically reduced to smaller pieces with a bone cutter in sterile conditions and incubated at 37° C. in 5% CO₂ in a 100 mm culture dish in presence of DMEM medium containing 10% fetal bovine serum (FBS) (certified FBS, Invitrogen, Burlington, ON, Canada) and 1% penicillin/streptomycin (Invitrogen). After a 30-day period, the osteoblasts derived from the bone pieces were separated at confluence from the remaining bone fragments by trypsinization.

Total RNA Isolation and RT-PCR

[0067] Extraction of RNA from osteoblasts was done using the standard Trisol Reagent method. (Invitrogen).

[0068] The RNA obtained from the osteoblasts was used for cDNA synthesis performed with the Invitrogen Thermo-script™ RT-PCR system and the respective protocol in the following conditions: Enzyme used: Taq DNA polymerase from Invitrogen™. PCR conditions: 95° C. 5minutes, Hot start (1 cycle). Following three reactions (32 cycles): 94° C., 45 Seconds Denaturation; 55° C. 45 Seconds; Primer annealing; 72° C. 1 minute Elongation; 72° C. 2 minutes Last elongation (1 cycle); 4° C. 20 minutes pause; Duration: 2 hours 42 minutes. The quality of the cDNA was tested by amplifying 233 bp fragment of human beta-actin using the sense primer 5'-GGAAATCGTGCGTGACAT-3' (SEQ ID NO: 4) and antisense primer 5'-TCATGATGGAGTTGAATGTAGTT-3' (SEQ ID NO: 5). For quantitative analysis, all amplifications were normalized against that of the house-keeping gene β -actin. PCR amplified product were separated on 1.5% agarose gel and visualized by ethidium bromide staining.

Expression Analysis of Pitx1:

[0069] Coding region of Pitx1 501 bp in length was amplified from the cDNA using the sense primer 5'-GACCCAGC-CAAGAAGAAGAA-3' (SEQ ID NO: 6) and the antisense primer 5'-GAGGTTGTTGATGTTGTTGAGG-3' (SEQ ID NO: 7) under the following PCR conditions: Enzyme used: Taq DNA polymerase from Invitrogen™. PCR conditions: 95° C. 10 minutes hot start (1 cycle); Following three reactions (34 cycles): 94° C. 45 Seconds Denaturation; 69° C. 45 Seconds Primer annealing; 72° C. 1 minute Elongation; 72° C. 2 minutes Last elongation (1 cycle); 4° C. 20 minutes; 4° C. Pause; Duration: 2 hours 34 minutes 11 seconds.

Pitx1 Promoter Sequencing

[0070] 10 kb region of the pitx1 promoter was amplified and sequenced to screen for mutations. Enzyme used: Platinum® Taq DNA polymerase High fidelity from Invitrogen™ under the following conditions: 95° C. 5 minutes hot start (1 cycle). Following three reactions 35 cycles: 94° C. 45 Seconds Denaturation; 61.8° C. 45 Seconds Primer annealing; 72° C. 1 minute Elongation; 72° C. 5 minutes Last elongation (1 cycle); 4° C. 20 minutes; and 4° C. Pause.

[0071] One hundred (100) ng of genomic DNA was mixed in a final volume of 25 μ l containing 200 micromolar dNTPs, 1,5 mM MgCl₂, 10 pM of each primer (see Table 4 below for list of primers used), and 1U Pfx DNA-polymerase (Invitrogen) or an other DNA polymerase.

[0072] PCR conditions: Regions PP1, PP2, PP3, PP6, PP7 were amplified using Platinum® pfx DNA polymerase from Invitrogen™ under the following PCR conditions: 95° C. 5 minutes hot start (1 cycle); Following three reactions (35 cycles): 94° C. 30 Seconds Denaturation; 60° C. 30 Seconds; Primer annealing; 68° C. 1 min 20 Sec Elongation; 68° C. 2 minutes; Last elongation (1 cycle); 4° C. 20 minutes; 4° C. Pause. Duration : 2 hours 35 minutes 26 seconds

[0073] Regions PP4, PP5, PP8, PP9 and PP10 were amplified using Platinum®Taq DNA polymerase High fidelity from Invitrogen™ under the following conditions. 95° C. 2 minutes hot start (1 cycle); Following three reactions (35 cycles); 94° C. 45 Seconds Denaturation; 60° C. 45 Seconds Primer annealing; 72° C. 1 min 20 Sec Elongation; 72° C. 5

minutes Last elongation (1 cycle); 4° C. 20 minutes; 4° C. Pause; Duration : 2 hours 53 minutes 4 seconds.

TABLE 4

PITx PROMOTER PRIMERS	
PP1 (962 bp)	forward primer 5'-CTGTTTGCTCAAGACGCTGA-3'; (SEQ ID NO: 8) reverse primer 5'-CTCGGCTCACAAAAGAAAC-3' (SEQ ID NO: 9)
PP2 (966 bp)	forward primer 5'-TGTCGTCATTCAGGCTGTTC-3'; (SEQ ID NO: 10) reverse primer 5'-GATTCCCTCCTCGAGTCCTT-3' (SEQ ID NO: 11)
PP3 (1039 bp)	forward primer 5'-CAAGTGAGCTGGATGCTGAA-3'; (SEQ ID NO: 12) reverse primer 5'-AGGGAGTGTCCCTTCACAGA-3' (SEQ ID NO: 13)
PP4 (1085 bp)	forward primer 5'-GCTCAGCCATTCTCAGGAAC-3'; (SEQ ID NO: 14) reverse primer 5'-GCCATTGTCCAGTCAAGAT-3' (SEQ ID NO: 15)
PP5 (1011 bp)	forward primer 5'-TCGCGTCAAGAGGGTATTTT-3'; (SEQ ID NO: 16) reverse primer 5'-TAGGACCCATGGCTCTACCC-3' (SEQ ID NO: 17)
PP6 (1098 bp)	forward primer 5'-CACGAGTCAGGTGGGAAACT-3'; (SEQ ID NO: 18) reverse primer 5'-GACGTCGTCTGCTTTTCTGC-3' (SEQ ID NO: 19)
PP7 (963 bp)	forward primer 5'-AGGCACGGACTAGCAGGAC-3'; (SEQ ID NO: 20) reverse primer 5'-ATGCGGACGAAGCCAGAG-3' (SEQ ID NO: 21)
PP8 (986 bp)	forward primer 5'-TTAGCATTCAGCCCCTCTGT-3'; (SEQ ID NO: 22) reverse primer 5'-TTCATGAGATGCAGTCAGCAG-3' (SEQ ID NO: 23)
PP9 (951 bp)	forward primer 5'-ACAACGGTAGGGCAACAG-3'; (SEQ ID NO: 24) reverse primer 5'-TGTGTGGCTTTGGCAAATAA-3' (SEQ ID NO: 25)
PP10 (990 bp)	forward primer 5'-GCACTGTGCTCCAACACTGTGT-3'; (SEQ ID NO: 26) reverse primer 5'-GGGGAGTGTCTTTTCCTT-3' (SEQ ID NO: 27)

EXAMPLE 1

Comparison of Pitx1 Expression in Osteoblasts of AIS Subjects with That in Osteoblast of Matched Controls

[0074] To determine whether pitx1 plays a role in the genetic control of AIS development and/or progression, an expression analysis of pitx1 gene using RNA prepared from osteoblasts cultures derived from biopsies obtained intraoperatively of severely affected AIS patients (n=46) and from non-scoliotic patients (trauma cases) control subjects (n=29) was performed.

[0075] As may be seen in FIG. 1, all osteoblasts derived from the AIS patients showed a loss of pitx1 mRNA expression, while control subjects still expressed the mRNA.

EXAMPLE 2

Determination of Pitx1 Expression in a Subject Sample

[0076] Tissue such as muscle (using for instance a needle in the paraspinal region), bone, cartilage, peripheral blood

mononuclear cells (PBMCs such as T and B lymphocytes as well as macrophages) or any cells derived from tissues where Pitx1 is expressed is isolated from the patient. Extraction of RNA from these tissues is done using any standard RNA extraction method such as the standard Trisol Reagent method. Coding region of Pitx1 501 bp in length is amplified from the cDNA using for instance RT-PCR or real-time PCR. The sense primer 5'- GACCCAGCCAAGAAGAAGAA-3' (SEQ ID NO: 6) and the antisense primer 5'- GAGGTTGT-TGATGTTGTTGAGG-3' (SEQ ID NO: 7) under the following PCR conditions: Enzyme used: Taq DNA polymerase from Invitrogen™, PCR conditions: 95° C. 5minutes Hot start (1 cycle). Following three reactions (32 cycles): 94° C. 45 Seconds Denaturation; 55° C. 45 Seconds Primer annealing; 72° C. 1 minute Elongation; 72° C. 2 minutes Last elongation (1 cycle); and 4° C. 20 minutes pause. Duration: 2 hours 42 minutes.

[0077] Although the present invention has been described herein above by way of specific embodiments thereof, it can be modified, without departing from the spirit and nature of the subject invention as defined in the appended claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 27

<210> SEQ ID NO 1

<211> LENGTH: 10006

<212> TYPE: DNA

<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 1

```

cccaaatgt ctatctgtga tagtggctgt gcccttcgg gccctgagca ccctgtgtcc      60
tgtgcagcag tcagatatct ggaggagac tgaggcactg gctgcagagc ttgtgatcat      120
gagagagact cactaggact acagatgggt aaactgaggc ctctgagggg gcagctccag      180
aaaggcaggg gccataatgt ctcacctca tatttcccg gccaaactgt ggccttctgc      240
attcatggca gatgagtga caaaggctga tggactgatg gagaaacaaa gggatagatg      300
gagcagctgg gcagctcagc aatgatgct gcaatgatct gcttccaact cacctcaaat      360
ccatccttct ctctccagcg agagtgggct ttaagatac acatctggcc aggtctctca      420
ctgttcaaac ccttcactct ctctcttttg ccttcaggat aacatccca cctcctatca      480
aggactatgg agccctgtgg gatctgggtc cacttgatt ctccaacttc ctcttccct      540
atgccctgcc ttctcactctg ttccagtctg attatgaagc cacacgttct tcctttatta      600
tcaagcatac cacagtttat ctcacctcag aggctttgca cagtatattt tcctagggag      660
gggtccccag gtggtagaaa aacggttaca gccaactcct ccatgtgtca ctcaagacc      720
ttcaacagca ggctgcagat ttctctcca gcactgtgct ccaactgtgt aatggatttc      780
tgtgtctgcc tccttgactc aacccaaatg aacaagagcc atctatctct gtatctctgc      840
aatcacagcg acaaaatagg tgctctctac atttttoca acctgagagg ccattctaga      900
agggtctcag gccacggttc tgtccagtat tccatgcaga tgctgacagg actgcaatta      960
aaaaatact tgagatgccc aatgcccac atagcttctc attttgcttt gactaccaat      1020
aattgcacag tgcaatagaa taatgctcaa atacattaac atcttacttg atcctagggg      1080

```

-continued

gtcctctcta cttttaaagc ctcaaaacttc ctcctctctca caggtgaaaa ggggagtaca	1140
aatacattcc ctcccttgct ctgcccgatcc attcctacag gtagtcaaga ctctgagctt	1200
cccctctgac tttctggcag tgcttcacct ctccccacag atgagtgcag gaacaattct	1260
aacagacttc agactcttcc aacagagcca atccctcccc atcacgttgg agtggacttg	1320
ctaccacac catcaacagg cccctgagaa acttcacagg gcaggggctt ctttggtaaa	1380
accaaccctt tcttccacc agctcagaga agttgttcca gatagatgcc aggattcttg	1440
gaggagcatg gtgattctgg ggtggagcct ctgacctgg ccaaccaag gcctgagcca	1500
ctcttcccc acaaatgat tggcgcagga gtgggcatgt aagctggacc cagccaatca	1560
gcataaccaa atcccttgcc caccctgggg agggctctat agttgttgc aagagaggct	1620
caccctggt ctcaagaagc ttacaactgg taggggcaac aggttttaat ctatcattac	1680
acaaatattt aatttcaata ctgttgcaat aagagctatg aaggaaaaga aactcccc	1740
tacttttact tgggttgaag atttgaagaa gaaaaaaaa aaacactgcc tgaaggattg	1800
ttatggcctt ctatataata gtggctgcag acatttgccc attatgttca gcatgaacco	1860
atgtgacaaa tcatcaaag cgttttgcc tagggagaaa aatttgtatt agaggaagca	1920
cagcagtttg gactgaaaga caaagaaaaa tcagccaatt ctgctgatct tttttgatgg	1980
ggcacctgga agctgaaagc taaagtggta ctcaggaaca gggactgcta cttctgttcc	2040
tggtgaatcc tgccccaac ctctctctc tctgattcct gattccactg tgccagtggg	2100
aatatatget cccaagatg tcaaaactaa agggaaattg caaaaaatat atacatata	2160
ttttagagag aaaataagat tataaaaaat gtgttttga ccccccaagt ttcactaaga	2220
acttctgac ttccaggccc tggttgtgccc ccacgcacca gcctgcccag ctttctgga	2280
ccaaacttcc tagcacctaa gcaggggatg agggcagata aactaaatca gaaaagggat	2340
ctgttctccc tagactcaac caacatgacc accgtgggga aagaagaaac aaaaacaaga	2400
gcaaactctc ttaaagagca gcctggcagc tatcaccatt agcattcagc ccctctgtcc	2460
acaggactca ggaccaaac cctcaccttc actatcccat ccgtttccca agaagcagaa	2520
atacttattc tcacatttca cagatgggga agctgaggct aggagagggt atgttatttg	2580
ccaaagccac acaactagta aaagccactg acaagattct ggctcaggcc atcaggtgcc	2640
agaggcagca ttttttggca ccacaggccc tgctgggaa caagagcatg cagaaaatct	2700
cacaagagat gggaaacaaa tttggaaaat tgctagcgtg caggagggg ggaaggtgtg	2760
atttctgct acagacgcca gagtaaaagc cccccagga gtgcctgtgc agccctccat	2820
agtaaggtcc agcggctgca tttatgcca aagatgcccc tgggtcttgg agtgaagga	2880
agattccaga gacaagatta gaaacttctc agcttagcag ctctagggct ggaccgcca	2940
acaagccatt ttacacataa agcagtcaat gggagggggt agacgtaggg ggctaaactc	3000
cccacagcac agggctcaag ttggttagact gcactttctc caggcagcagg tccgctagtg	3060
ccggcatcgg ggactcgta tcttaacttg cgacctggg tgacacagac cctgcacaca	3120
ccactggaga ggggttctct ctgtcgaggg ttgagaggag ggtatggagt ccctggaaca	3180
gcacgacagg gtgcagaggc cacctggcag ggctgaaca ccgaggctc tgtgagcttg	3240
ggctgggccc gcttcccgtc tcggaggttg gggagggggt cgtgggtctc tgcgttcca	3300
ggccaagcgg cctggaggc acggactagc aggaacgcca ggtggcgcgg gtcgcccct	3360

-continued

ctccccagc agctgtcggc gagaaccagg cagggaggcg ccgctgctga ctgcatctca	3420
tgaaagattc aggcccggtc gccgcgctgc catctcccgg caccttgcgc cggaaacggt	3480
cgctctggag cccgtggccg tcgpcgggca ggcttagccg ctccagtccc tgagaaaggc	3540
aggccacagc ccgacctgcc ctgtgggtccc atcccataat cccaacagca agcaggctca	3600
ggctggggcac ttcggggtag caggagtagg ttcggccaac tggtttccac catgaggctt	3660
cgcgcacagg gttatctggc caccaggcaa cgctggggag ccctgtggcc tgagggtggg	3720
caaaggacag gctcccagtt cccttgcgct cagcccgtct cccagcggca gccagccagg	3780
aacggcctgc ggggccacag ggggtggagg gtcaccgttc gcaggcccgc agcaggatgg	3840
tcgctggggg atgtgcaggc ataggggttg gacaaggggc cccagaagtg tctgtcctga	3900
ggggttggtg tgccttttc tcaccagccc agcccctgag gagagggaag aaggcaattc	3960
ccccaacagc ggcaggctcg gcggttgccc caccctaaca ccccctacc ccaaacacag	4020
aaaacctggg gtctgtcctc aaacctcctt ggctgccacg ctctgggcag cggactctcc	4080
ctgccaacac gcaagaccag ctccctcccg caggctgagc agaaagaaga aaggtccaat	4140
ctcaaaacc caaactcgac caccagcccc cgtctaaacg gaagtagggc cagcccctca	4200
cgagtcaggt gggaaactgg gcccaggggag agaaagtgcc ccagggccag gctgggaacc	4260
gctctggctt cgtccgcatg cggcagggcc cctccacgga ggtcccaggc cgcgctcccc	4320
ggcctcgagg cccggccgcc agccgcgctg accccagcct acgcccagag ggaggccagg	4380
accctagcc ggcgggactg cgcgcgcccc ctctccccgc aggtcccggc gaacacctag	4440
cttccccctc ccccaccctt cccgcctccc ggccagtgtc cccgccttc ccgcgggcga	4500
cgggcggcgg cggcgggagg agcggggcca gccgaggaag ccccgccctc gcgctgggg	4560
atgtagcga ccagcagggg ccgaagaacc gtgcagtgcc agagccagag ctggatccgg	4620
ggccccagcc ggagccgaaa cctgagccag agtccgcggc gggcgagccc ggagcccag	4680
agccgcagac gcagcctgc ccaggtgggg taagagacgc tgggctaggg gcgcagggtc	4740
tccgcggttg aggggcgcag ggaggtggcg gccgagtcct gcgcagtttg ctctggcgt	4800
gtgtgggtcc acccgcgccg gcgggacagc gcaagcgcgc gaaggtcagg agccttcgag	4860
gcagcgcgag gagctcgttc ctgcgccag gccacagtca tagccgccgt caccgggtgc	4920
tacctcacc aaccggcggg atcaaccctc tgetttggct ccggggacct caagagggtta	4980
gcagcctcgg gggcacgggc caccgccccg cgaagggcac aacctgagaa gcccgaggca	5040
gcccctcgca gcgtcgggtg acacagggtc ccccccccc caggagaagt gggcaggaga	5100
gagggccgcc cgtctctccc cgtctcgtcc agggatggag gggcccacca cccatggaat	5160
tgtggcccc tctgcgtggc ccgggacttc agccgtggct tcgctcaag agggatattt	5220
tcctaaacga aaccgcttcg ttcgttcggt cgttcgttcg ttcgggcagc aatgccgcag	5280
aaaagcagca gacgtcggtc cgcgccctgg ctctcttcgc cccggacccc gacgtcccgc	5340
cgcagcgtc ggaggtgccc ccagcccag gcagcctgct ctgcgccgca caggtcgggc	5400
ttttctctcc caggagagaa accccaattc ccttcgtaac gtccaataaa gacattcccg	5460
cggtctctcc caggtttgtg tgttgacgca gggcccggca gcacgcagtc gcttctcaag	5520
aaccgggtct cggatttctg aaattgaaca gcttcgtaaa ttggagccta ttctcccgcg	5580
gcaaaggcag ggcaccaaaag ccgggatcgc agtaatggga accccaggct ggaatccggg	5640

-continued

tcccaagctt	ttccgattta	ggaattcccc	gaatctacaa	atatttagtc	cactttctg	5700
aaaaactaaa	ttctgaaaaa	cacaaattct	cttgacatcc	ctgtgacctc	tгааagccac	5760
cagggccaga	gggaggaaat	cccagggtgc	tgtccactgg	gggaggatc	aggtctaggg	5820
ttcaggtcta	cggtagtcag	ggcaaaagct	acaggcagca	ggggcagcac	aggagacttg	5880
ctgtccccgt	gcccctttccc	ggggctgctt	tcggcctccc	gcactctctc	cagggaaagg	5940
aaaagaggtg	ggctggggct	tggagaccag	gctgtctgga	ctctaggatg	cagaggcctc	6000
cagacaggct	caggggtgctc	ttctcccatg	aaagcagccg	ctgggaggag	gaggctatgg	6060
tgcattccata	agttgcccc	ctgtccccca	gttgtgcgac	cagctgtctac	ctccttccca	6120
gtcttcttcc	ccacagctca	gccattctca	ggaaccagac	agcgtccatg	gacttaggtg	6180
agagatgggc	cggttagagc	catgggtcct	accagccgct	gactgagcgg	cccacggcac	6240
agagtcctga	gttcatact	cccactctgtg	cctcactggc	ggcagtcctg	ctcaaataca	6300
tcctggctct	ccccgggaca	ggctggggat	ccccatttgg	caggaagcct	cagactgggg	6360
tcccaggaag	cctaaaggag	ccagtgaggt	ctttccagcc	cctacctgag	caccctctc	6420
cccacttacc	cagtaattgc	tgtattcaaa	gaaacgggag	cttttattgg	ggagggggtg	6480
ttagatcagg	cagaaagagg	taggtggctc	aaacctgcac	tccccaaaaca	gggttttcaa	6540
gtttgaactt	ctccacggac	taagaggctt	agggttgaa	tgtcccagag	agtcattggat	6600
agccctggtg	gcaggccatg	gcacattcct	tcctttttcc	taaaatacct	tgattctggg	6660
agcaaggatt	agggcacggt	gccccctggg	gtgggtagaa	ggatgcccc	cactgagag	6720
cctccaacc	acccttcccc	aattacatta	ctaaaccatt	cttgggcaca	gggtgttttt	6780
agtgagccag	gcttcaggaa	gggtctctcat	ggtgactact	tcaacccac	aacagcccaa	6840
gctcttctgc	tcagcccagc	caagacccta	aaactcaaaa	ttcttgaaaa	tcagagaatc	6900
attgctggct	ttgtgtggct	acggaggggt	ggggaacagg	gcacatggtt	ccagctccac	6960
taagccccct	tcctctctct	cttcgtgtcc	catcagcaag	tgagctggat	gctgaagcag	7020
caggcagagt	ccgggtgttg	acatgggaac	tgaggcacag	tgagatcaa	gccttaacct	7080
tgagggaaac	acaggtcaca	tagcacagct	gggggaacac	aaagcctctg	cttactcctg	7140
aaagagtct	gttttctgtc	ctgtatgtgt	gacgtgtctg	tgagcgtgca	agaagcccct	7200
atcttgactg	ggacaatggc	cagtgagtgt	agctggggaa	gaattgagag	catgtccagg	7260
tccttcccc	agccaacgcc	caagatcagg	ccacagcctc	ctcaaatca	attgcctcct	7320
cactccttga	tcactcagtg	ctgcccaggc	ccagcagaac	agactctgcc	agcaggcccc	7380
actagcccca	gctcctcttt	gggtctcagg	tcccctgagg	atatggggct	tcacctgaaa	7440
tggctcagag	gcttttctct	ctacacagca	ggcatcaaga	tcaccaaata	aagggactat	7500
tgtgctgccc	tggagccctg	ccagaggttt	gggccagag	gggcacacag	caggtgctca	7560
ataactgcat	taaatgcact	aacagtgagg	aaacacgccc	ctcagactaa	gcagtgagtg	7620
ctgctcacag	aatagtcccc	attgggggat	ggcccaaaga	gtcactttgg	tcctctggg	7680
aagtgagaag	gcaagtgaga	aggctgtgag	tcttaacctc	ctctagaggc	ccacagacag	7740
accattcatt	tctaagtctc	taccagaga	cgcactgtgc	ttcccacctt	ggcctgacat	7800
gtggcagggt	tagaacacac	ctcctatccc	ctgccagccc	gogttcatgc	caagtagcac	7860
atatatgctt	aaactcagca	cttccatagt	gcagtgaata	catgtgtgtg	tacagcatct	7920

-continued

ccgcattgat	gtacaggatg	tgtgtgtgtg	tgcgtgcccc	catgctgtct	gcattcaggc	7980
tgttcttttt	ggtaagacag	ctaaaaaaag	aatggctctgt	gaaggacac	tccttagcac	8040
gctgcaacac	ctgaatatct	ccttgaaagg	agggatcttc	tactgcagga	gactcgtggt	8100
aaaggtggcc	aagaaacatg	gcaacgggtg	ggctgagggc	aatgctggg	caactgtgct	8160
tccccatggt	cccctcccc	tagccaagac	tcatttcctg	gagggagatc	tcagcttgga	8220
agaaggcagg	agtcactgag	cctccccaat	ccaaaccctc	gagaagtgc	ctccctctgg	8280
cctcagacc	tgcatcctgt	ggtcacagac	ccacagtgag	aaaggaccag	gccctaagga	8340
gctgtgctgt	ctctccacgg	cccagagcgg	gggatgggga	tggggatggg	gatggggatg	8400
gggatgggga	tgggggtagg	gggtgggggtg	ctttggacta	acgtggaggg	aatggaaggc	8460
aggcctggtt	ccaccctgca	tgcccagacc	tggccccagc	agccccaca	aggagctcag	8520
ctgaccctgg	gtgtctccct	gtgatgggaa	ggggaagac	gaggactcaa	aggcagaacc	8580
tgcagagtgc	cccagacgct	gatacctgca	cagtcagtgc	caccaccca	ggagttgagg	8640
aggcactggg	ttttgggggtg	aggacactgg	acacctccct	gcttctttcc	caggcagaca	8700
atcctggcgc	agctcccttg	ggttgctgtg	tctggtggag	ctgatcacag	gtgaggggca	8760
gagggcagtc	tggggtccgc	ctatggccag	aggagcaggt	cagggcggcg	ccttgccgcc	8820
ccagctgtgg	cctgtttgct	caagacgctg	aggtctcggg	gccagctaac	aattgttgag	8880
caaaaacctt	cgacaaaact	cacctacgtg	caaggactcg	aggagggaat	cactcttagg	8940
agtgggagag	taatgtcttt	gcctgtgccc	agtgaaggcc	cattggaget	gcagctcagc	9000
taccactgtg	tgggagagaa	gctggaagac	tgaggcttcc	ctgggctgct	ggcccagggt	9060
tgggagacag	cagtcacctg	gcttaccagg	cctatgcctg	aagccctggg	aagccaggac	9120
gcaggcccca	ggctgggaca	aagctaccct	gaaggagggc	aaaggctgcc	aaggccaacc	9180
ccatgcctgc	caaggccagg	cctggcccat	ttggccaagg	cctaaggtgt	aaaaaagggt	9240
gagaggtaca	agaggctgtg	gggtctggct	gggatccttg	gggtcttctc	tctgcattct	9300
ccaaaacgct	agagccagca	gaaacgttcc	gtctgattag	aagccatcat	ttctatccca	9360
atcccggaaa	attgactgct	gtgcagagag	ggaggcctga	gaagcagccg	taggggagaa	9420
ggccaagct	aattaggagg	cagcatccgg	gggcccatta	gagcgcaggc	tgctgtcact	9480
cagccgggct	gagttcccg	gagaagaggc	tggagaagga	ggggcaggcg	gcccctcgac	9540
gaggacacc	ctgggagctg	ccggaacggg	ccccgggctc	tgccccgcc	ccggcgctgg	9600
ctcgaaggcg	ccgcctcgg	gcgatcctgt	tgggcaaca	ttcactcacc	ctgggctggt	9660
ctcgcagggg	ctggggactt	cgaggcggcc	gagacgggag	tgattcttag	gcgaaacaag	9720
tcatttgagg	cctgagggtg	gcacgagccg	cccgggactc	gcaggccaga	tcggtttctt	9780
ttgtgaggcc	gagggagaac	tcggtgtgtc	accggggaag	gagggagagg	cgcgccgagg	9840
ccgcgggggg	cggggagggc	cggggaaggt	ggctgcggag	ggggagggcg	cgggcgaggc	9900
agggagggag	ggagggcggc	agtgagggcg	cgggcgcgcg	ggcggttgg	ggctggattc	9960
cgcccgctct	ccctcgcctg	ctcgcctcct	ccccagcccc	ctccca		10006

<210> SEQ ID NO 2

<211> LENGTH: 2373

<212> TYPE: DNA

<213> ORGANISM: Homo Sapiens

-continued

<400> SEQUENCE: 2

```

cccaggccca ccccaccag caccctggc gcagggactg ctggaacctg gctgtgcgcg      60
ctgtcgcttt aagacagact ctgccggcgc cgtccggagc cttagaaacc ggccccggat      120
cgcgagcccg agccggagcc ggagccgggg ccggccgggc tgctgaggcc cgagcggcag      180
gagcgcagcg cggagcgctg agccaggcgc ccagtcgcga gaagctgccg ccgcctctgc      240
ccgccccggc ccgcagcccc gggcgggtcca tggggcgggc acggcgtcgc tgcaggcgcc      300
ggcagccctg gagggcagcc gcttaggcgc tgcgctcttg tccccgagg tcgcagccag      360
ggcggcgggg cgcgccagcc cccggccctt ggagcgcccg ccgcggtccc cactctcatg      420
gacgccttca aggggggcat gagcctggag cggctgccgg agggggtccg gccgcccggc      480
ccgccacccc atgacatggg gcccgcttc cactggccc ggcccgcga cccccgcgag      540
ccgctcgaga actccgccag cgagtctct gacacggagc tgccagagaa ggagcgcggc      600
ggggaaccca agggggccca ggacagtggg gcgggaggca cgggctgcgg cgcgcgagac      660
gaccocagcca agaagaagaa gcagcggcgg caacgtacgc acttcacaag ccagcagttg      720
caagagctag aggccacgtt ccagaggaac cgtaccccc acatgagcat gagggaggag      780
atcgccgtgt ggaccaacct caccgagccg cgcgtgcccg tctggttcaa gaaccggcga      840
gccaagtggc gtaagcgcga gcgtaaccag cagctggacc tgtgcaaggg tggctacgtg      900
ccgcagttca gcggcctagt gcagccctac gaggacgtgt acgcccgcgg ctactcctac      960
aacaactggg ccgccaagag cctgggccca gcgccctct caccacaagag ctteacette     1020
ttcaactcca tgagcccgtt gtcgtcgcag tccatgttct cagcaccag ctccatctcc     1080
tccatgacca tgcgtccag catgggcccc ggccgctgct ctggcatgcc caactcgggc     1140
ctcaacaaca tcaacaacct caccggctcc tcgctcaact cggccatgct gccggcgct     1200
tgcccgtacg gcactccgc ctcgccctac agcgtctacc gggacacgtg caactcgagc     1260
ctagccagcc tgcggctcaa gtccaaacag cactcgtcgt ttggctacgg cgcctgcag     1320
ggcccggcct cgggctcaa cgcgtgccag tacaacagct gaccgccccg ccgcaccaag     1380
cgggcccggc gccggagcgg ggaagggcgc gggcgcggag gacgcacgcg gggccccggc     1440
tcgcaagccc cagctcaccg gcgccggac ctcacacctg cgcagcccc tcctcccaact     1500
tcccactccg ggttggtttt gtgtttgctt ttccggaccc cactctgccc tccaaaaaga     1560
caaaaaaaaa aaaaaaaaaa aaagcaaaa gacgtcggag aaaagtgccg cgaaaaaatg     1620
gatgagttgc aatttctctc gggatggcgc ggggtggtgt tgtgtgttcc caeggcccc     1680
ggaggccca ccccgagagg gcaacggcgc cggtaggcga gcgcccaggg ccagcggccg     1740
ggggaggacg acctcgtatc ccgctcccc gccgcgctgg atccggactg agtggccggg     1800
cctcgggact ggatgtgcgg ggctggact tgcctaggat ttcccagccc cgtacaaacc     1860
aagttgcct ctcgagcta ggcgccgccc agagcgcctt agctcgagtc ggatccgtgt     1920
tggggcgggc gttgggtttg gggggacggt gccccagcc caggatcggg cactcagttg     1980
agccgcacac ggccccggcg cgcctggtag agcctcgtg gccccgcgc ccggagccct     2040
atattaaggc caggagcga cagcgggcag tgcggcctg gcgggaggtg ggggaggtcc     2100
atctcagaac accccagcct tgagcttagc tgcaggccca ggcctctgc tctgctcccg     2160
ggctaggagg tggccctctg tctgggcgaa cagccccctc ctcaccgccc gccgtgcaag     2220

```

-continued

```

agtcgagccg gcagagcaag gggcgcgccc ccaggccctt gcgccactt tgcacacccg 2280
ctctccggcc cgcgcccttg ttacacagct ccctgtgtat gttggactga ctgtaataaa 2340
tctgtctata tcgactaaaa aaaaaaaaaa aaa 2373

```

```

<210> SEQ ID NO 3
<211> LENGTH: 314
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

```

```

<400> SEQUENCE: 3

```

```

Met Asp Ala Phe Lys Gly Gly Met Ser Leu Glu Arg Leu Pro Glu Gly
1 5 10 15
Leu Arg Pro Pro Pro Pro Pro His Asp Met Gly Pro Ala Phe His
20 25 30
Leu Ala Arg Pro Ala Asp Pro Arg Glu Pro Leu Glu Asn Ser Ala Ser
35 40 45
Glu Ser Ser Asp Thr Glu Leu Pro Glu Lys Glu Arg Gly Gly Glu Pro
50 55 60
Lys Gly Pro Glu Asp Ser Gly Ala Gly Gly Thr Gly Cys Gly Gly Ala
65 70 75 80
Asp Asp Pro Ala Lys Lys Lys Lys Gln Arg Arg Gln Arg Thr His Phe
85 90 95
Thr Ser Gln Gln Leu Gln Glu Leu Glu Ala Thr Phe Gln Arg Asn Arg
100 105 110
Tyr Pro Asp Met Ser Met Arg Glu Glu Ile Ala Val Trp Thr Asn Leu
115 120 125
Thr Glu Pro Arg Val Arg Val Trp Phe Lys Asn Arg Arg Ala Lys Trp
130 135 140
Arg Lys Arg Glu Arg Asn Gln Gln Leu Asp Leu Cys Lys Gly Gly Tyr
145 150 155 160
Val Pro Gln Phe Ser Gly Leu Val Gln Pro Tyr Glu Asp Val Tyr Ala
165 170 175
Ala Gly Tyr Ser Tyr Asn Asn Trp Ala Ala Lys Ser Leu Ala Pro Ala
180 185 190
Pro Leu Ser Thr Lys Ser Phe Thr Phe Phe Asn Ser Met Ser Pro Leu
195 200 205
Ser Ser Gln Ser Met Phe Ser Ala Pro Ser Ser Ile Ser Ser Met Thr
210 215 220
Met Pro Ser Ser Met Gly Pro Gly Ala Val Pro Gly Met Pro Asn Ser
225 230 235 240
Gly Leu Asn Asn Ile Asn Asn Leu Thr Gly Ser Ser Leu Asn Ser Ala
245 250 255
Met Ser Pro Gly Ala Cys Pro Tyr Gly Thr Pro Ala Ser Pro Tyr Ser
260 265 270
Val Tyr Arg Asp Thr Cys Asn Ser Ser Leu Ala Ser Leu Arg Leu Lys
275 280 285
Ser Lys Gln His Ser Ser Phe Gly Tyr Gly Ala Leu Gln Gly Pro Ala
290 295 300
Ser Gly Leu Asn Ala Cys Gln Tyr Asn Ser
305 310

```

```

<210> SEQ ID NO 4

```

-continued

<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 4

ggaaatcgtg cgtgacat 18

<210> SEQ ID NO 5
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 5

tcatgatgga gttgaatgta gtt 23

<210> SEQ ID NO 6
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 6

gaccagcca agaagaagaa 20

<210> SEQ ID NO 7
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 7

gaggttgtg atgttgttga gg 22

<210> SEQ ID NO 8
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 8

ctgtttgctc aagacgctga 20

<210> SEQ ID NO 9
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 9

ctcgcctca caaaagaaac 20

<210> SEQ ID NO 10
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 10

tgtctgcatt caggtgttc 20

<210> SEQ ID NO 11

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 11

gattccctcc tcgagtcctt 20

<210> SEQ ID NO 12

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 12

caagtgagct ggatgctgaa 20

<210> SEQ ID NO 13

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 13

agggagtgtc cttcacaga 20

<210> SEQ ID NO 14

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 14

gctcagccat tctcaggaac 20

<210> SEQ ID NO 15

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 15

gccattgtcc cagtcaagat 20

<210> SEQ ID NO 16

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 16

-continued

tcgcgtcaag agggatattt 20

<210> SEQ ID NO 17
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 17

taggacccat ggctctaccc 20

<210> SEQ ID NO 18
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 18

cacgagtcag gtgggaaact 20

<210> SEQ ID NO 19
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 19

gacgtctgct gcttttctgc 20

<210> SEQ ID NO 20
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 20

aggcacggac tagcaggac 19

<210> SEQ ID NO 21
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 21

atgcggacga agccagag 18

<210> SEQ ID NO 22
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 22

ttagcattca gccctctgt 20

<210> SEQ ID NO 23

-continued

```

<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 23

ttcatgagat gcagtcagca g                               21

<210> SEQ ID NO 24
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 24

acaactggta ggggcaacag                               20

<210> SEQ ID NO 25
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 25

tgtgtggctt tggcaataa                               20

<210> SEQ ID NO 26
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 26

gcactgtgct ccaactgtgt                               20

<210> SEQ ID NO 27
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 27

gggggagtggt tcttttcctt                               20

```

1. A method of stratifying a subject having adolescent idiopathic scoliosis (AIS) comprising: providing a cell sample isolated from the subject; detecting Paired-like homeodomain transcription factor 1 (Pitx1) expression in the cell sample; whereby the results of the detecting step enables the stratification of the subject having AIS as belonging to an AIS subclass.

2. A method of stratifying a subject having adolescent idiopathic scoliosis (AIS) for a clinical trial comprising: providing a cell sample isolated from the subject; detecting Paired-like homeodomain transcription factor 1 (Pitx1) expression in the cell sample; and stratifying the subject for a clinical trial based on the results of the detecting step.

3. A method for predicting a risk for developing adolescent idiopathic scoliosis (AIS) in a subject comprising providing a cell sample isolated from the subject; and detecting Paired-like homeodomain transcription factor 1 (Pitx1) expression in the cell sample; wherein an absence of Pitx1 expression is indicative that the subject is at risk for developing AIS.

4. The method of claim 3, wherein an absence of Pitx1 expression is indicative that the subject is at risk for developing a Cobb's angle of 45° and above.

5. The method of claim 1 wherein the detecting step is performed with an isolated nucleic acid molecules specific to a Pitx1 transcription product.

6. The method of claim 5, wherein the isolated nucleic acid molecule is detectably labeled.

7. The method of claim 1 wherein the detecting step is performed with an antibody that binds specifically to Pitx1.

8. The method of claim 1, wherein the cell sample is selected from the group consisting of an osteoblasts sample, a chondrocytes sample, a skeletal myoblasts sample and a blood sample.

9. The method of claim 1, wherein the cell sample is an osteoblasts sample.

10. The method of claim 1, further comprising a step of selecting a preventive action or a treatment in light of the results of the detecting step.

11. The method of claim 3, wherein said subject is pre-diagnosed as being a likely candidate for developing adolescent idiopathic scoliosis.

12. A method of selecting a compound potentially useful in the treatment of adolescent idiopathic scoliosis, said method comprising the steps of

(a) contacting a test compound with at least one cell known to express Paired-like homeodomain transcription factor 1 (Pitx1); and

(b) determining Pitx1 expression level;

wherein the test compound is selected if Pitx1 expression level is increased in the presence of the test compound as compared to that in the absence thereof.

13. The method of claim 12, wherein said cell is an osteoblast.

14. The method of claim 12, wherein said cell is from a subject having adolescent idiopathic scoliosis (AIS).

15. The method of claim 1 wherein the subject is a human.

16. A kit comprising an isolated nucleic acid molecule specific to a transcription product of a Paired-like homeodomain transcription factor 1 (Pitx1) or an antibody specific to Pitx1, and instructions to use the isolated nucleic acid molecule to predict whether a subject is at risk for developing adolescent idiopathic scoliosis or to stratify a subject having adolescent idiopathic scoliosis.

17. (canceled)

18. The kit of claim 16, further comprising a container for a nucleotide sample from the subject.

19. (canceled)

20. (canceled)

21. The method of claim 3 wherein the detecting step is performed with an isolated nucleic acid molecules specific to a Pitx1 transcription product.

22. The method of claim 21, wherein the isolated nucleic acid molecule is detectably labeled.

23. The method of claim 3 wherein the detecting step is performed with an antibody that binds specifically to Pitx1.

24. The method of claim 3, wherein the cell sample is selected from the group consisting of an osteoblasts sample, a chondrocytes sample, a skeletal myoblasts sample and a blood sample.

25. The method of claim 3, wherein the cell sample is an osteoblasts sample.

26. The method of claim 3, further comprising a step of selecting a preventive action or a treatment in light of the results of the detecting step.

27. The method of claim 3 wherein the subject is a human.

* * * * *

专利名称(译)	分层青少年特发性脊柱侧凸的方法，用于其的分离的核酸分子和使用它们的试剂盒		
公开(公告)号	US20100173296A1	公开(公告)日	2010-07-08
申请号	US12/531740	申请日	2008-03-19
申请(专利权)人(译)	褚SAINTE-JUSTINE		
当前申请(专利权)人(译)	褚SAINTE-JUSTINE		
[标]发明人	MOREAU ALAIN		
发明人	MOREAU, ALAIN		
IPC分类号	C12Q1/68 C12Q1/02 G01N33/53		
CPC分类号	G01N2800/10 G01N33/6872		
优先权	60/908417 2007-03-28 US 60/895490 2007-03-19 US		
外部链接	Espacenet USPTO		

摘要(译)

一种对患有青少年特发性脊柱侧凸 (AIS) 的受试者进行分层的方法，包括：提供从受试者分离的细胞样品;检测细胞样本中的配对同源域转录因子1 (Pitxi) 表达;由此，检测步骤的结果使得能够将具有AIS的受试者分层为属于AIS亚类。




Figure 1